Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients.

Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X.

Med Oncol. 2011 Dec;28 Suppl 1:S129-34. doi: 10.1007/s12032-010-9742-6. Epub 2010 Nov 16.

PMID:
21080107
2.

Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.

Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X.

Med Oncol. 2011 Dec;28 Suppl 1:S31-8. doi: 10.1007/s12032-010-9676-z. Epub 2010 Sep 16.

PMID:
20844986
3.

ER, PgR, HER-2, Ki-67, topoisomerase II╬▒, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.

Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X.

Med Oncol. 2011 Dec;28 Suppl 1:S48-54. doi: 10.1007/s12032-010-9693-y. Epub 2010 Sep 25.

PMID:
20872186
4.
5.

Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.

Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H.

Anticancer Res. 2005 Nov-Dec;25(6C):4615-21.

6.

Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.

Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G.

Clin Breast Cancer. 2010 Jun;10(3):230-7. doi: 10.3816/CBC.2010.n.031.

PMID:
20497922
7.

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.

Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Vanden Bempt I.

J Clin Pathol. 2009 Jul;62(7):624-8. doi: 10.1136/jcp.2008.061358.

PMID:
19561231
8.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

9.

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL.

J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7.

PMID:
18180460
10.

Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.

Osako T, Horii R, Matsuura M, Ogiya A, Domoto K, Miyagi Y, Takahashi S, Ito Y, Iwase T, Akiyama F.

J Cancer Res Clin Oncol. 2010 Feb;136(2):233-41. doi: 10.1007/s00432-009-0654-9. Epub 2009 Aug 14.

PMID:
19685074
11.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

PMID:
19380449
13.
14.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
15.

Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer.

Tang Y, Zhu L, Li Y, Ji J, Li J, Yuan F, Wang D, Chen W, Huang O, Chen X, Wu J, Shen K, Loo WT, Chow LW.

J Transl Med. 2012 Sep 19;10 Suppl 1:S4. doi: 10.1186/1479-5876-10-S1-S4. Epub 2012 Sep 19.

16.

Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters.

Nakopoulou LL, Tsitsimelis D, Lazaris AC, Tzonou A, Gakiopoulou H, Dicoglou CC, Davaris PS.

Cancer Detect Prev. 1999;23(4):297-308.

PMID:
10403901
17.
19.

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.

Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, Kim JH, Nam SJ, Kim HJ, Ahn JS, Park YS, Lim HY, Han BK, Yang JH.

Cancer Chemother Pharmacol. 2008 Apr;61(4):569-77. Epub 2007 May 17.

PMID:
17508214
20.

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.

Tanioka M, Sakai K, Sudo T, Sakuma T, Kajimoto K, Hirokaga K, Takao S, Negoro S, Minami H, Nakagawa K, Nishio K.

Breast Cancer Res Treat. 2014 Oct;147(3):513-25. doi: 10.1007/s10549-014-3121-5. Epub 2014 Sep 9.

PMID:
25200445

Supplemental Content

Support Center